Cargando…
The impact of COVID-19 on opioid treatment programs in the United States
BACKGROUND: The COVID-19 pandemic had the potential to severely disrupt the delivery of methadone and buprenorphine, as social distancing and other public health regulations made in-person services difficult to maintain. Federal and state regulators changed requirements regarding the dispensing of m...
Autores principales: | Goldsamt, Lloyd A., Rosenblum, Andrew, Appel, Philip, Paris, Philip, Nazia, Nasreen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461004/ https://www.ncbi.nlm.nih.gov/pubmed/34600258 http://dx.doi.org/10.1016/j.drugalcdep.2021.109049 |
Ejemplares similares
-
Distance Traveled and Cross-State Commuting to Opioid Treatment Programs in the United States
por: Rosenblum, Andrew, et al.
Publicado: (2011) -
Age differences in heroin and prescription opioid abuse among enrolees into opioid treatment programs
por: Cleland, Charles M, et al.
Publicado: (2011) -
The Psychosocial Impact of COVID‐19 on Registered Nurses
por: Stimpfel, Amy Witkoski, et al.
Publicado: (2021) -
Impact of COVID-19-related methadone regulatory flexibilities: views of state opioid treatment authorities and program staff
por: Mitchell, Shannon Gwin, et al.
Publicado: (2023) -
The Impact of COVID-19 on Syringe Services Programs in the United States
por: Glick, Sara N., et al.
Publicado: (2020)